Sign In
Buy ARCT
$5.76
-0.160 (-2.70%)
At Close: Jul 31, 2026
Cathie Wood Goes Shopping: 3 Stocks She Just Bought
09:15am, Thursday, 23'rd Oct 2025
Cathie Wood bought shares of Robinhood Markets, Netflix, and Arcturus Therapeutics on Wednesday. Robinhood is one of the hottest stocks over the past year, cashing in on those with an appetite for spe
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture
03:05pm, Wednesday, 22'nd Oct 2025
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock was trading lower on Wednesday after the company shared interim results from its ongoing Phase 2 trial of ARCT-032, an investigational inhaled m
Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results
12:00pm, Wednesday, 22'nd Oct 2025
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) tumbled by more than 56% on Wednesday after the company reported interim results from its Phase 2 study of ARCT-032, an inhaled mRNA therap
Arcturus Crashes 55% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug
09:27am, Wednesday, 22'nd Oct 2025
Shares of Arcturus Therapeutics crashed more than 50% early Wednesday on mixed test results for its experimental cystic fibrosis treatment.
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
07:30am, Wednesday, 22'nd Oct 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last?
07:01am, Wednesday, 22'nd Oct 2025
Arcturus Therapeutics (ARCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
4 Stocks With Recent Price Strength to Maximize Your Gains
10:11am, Tuesday, 21'st Oct 2025
FLUX, AUGO, ARCT and STRL are showing notable price strength amid a volatile market.
Arcturus Therapeutics (ARCT) is on the Move, Here's Why the Trend Could be Sustainable
09:50am, Wednesday, 15'th Oct 2025
Arcturus Therapeutics (ARCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed
Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?
07:51am, Friday, 19'th Sep 2025
Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?
10:56am, Monday, 01'st Sep 2025
Arcturus Therapeutics Holdings Inc. (ARCT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ARCT's 50-day simple moving averag
Arcturus Therapeutics to Attend Upcoming Investor Conferences
04:01pm, Tuesday, 26'th Aug 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript
08:16pm, Monday, 11'th Aug 2025
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q2 2025 Earnings Conference August 11, 2025 4:30 PM ET Company Participants Andrew H. Sassine - CFO & Director Joseph E.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
07:56pm, Monday, 11'th Aug 2025
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to a loss of $0.64 per share a year ago.
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
04:01pm, Monday, 11'th Aug 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
04:01pm, Thursday, 24'th Jul 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
